{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:31:57Z","timestamp":1780979517560,"version":"3.54.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.rpsm.2012.05.005","type":"journal-article","created":{"date-parts":[[2012,7,24]],"date-time":"2012-07-24T05:49:26Z","timestamp":1343108966000},"page":"75-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["\u00bfDeber\u00eda considerarse la obesidad un factor limitante para el tratamiento con clozapina?"],"prefix":"10.1016","volume":"6","author":[{"given":"Alexandre","family":"Pons i Villanueva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Goti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Fernandez-Egea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Undurraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Carne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"68 Suppl","key":"10.1016\/j.rpsm.2012.05.005_bib0005","first-page":"13","article-title":"Antipsychotic medications: metabolic and cardiovascular risk","author":"Newcomer","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2012.05.005_bib0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"10.1016\/j.rpsm.2012.05.005_bib0015","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.rpsm.2012.05.005_bib0020","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1192\/bjp.bp.109.067512","article-title":"Twenty-five year mortality of a community cohort with schizophrenia","volume":"196","author":"Brown","year":"2010","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.rpsm.2012.05.005_bib0025","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.rpsm.2012.05.005_bib0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/JCP.0b013e31802e513a","article-title":"Weight gain during a double-blind multidosage clozapine study","volume":"27","author":"De Leon","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.rpsm.2012.05.005_bib0035","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S0006-3223(97)00488-5","article-title":"Clozapine and body mass change","volume":"43","author":"Frankenburg","year":"1998","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.rpsm.2012.05.005_bib0040","doi-asserted-by":"crossref","first-page":"751","DOI":"10.4088\/JCP.09m05402yel","article-title":"Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study","volume":"72","author":"Bai","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"Suppl. B","key":"10.1016\/j.rpsm.2012.05.005_bib0045","first-page":"157","article-title":"Clozapine and weight gain","volume":"55","author":"Umbricht","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2012.05.005_bib0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4088\/JCP.v62n0404","article-title":"Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone","volume":"62","author":"Basson","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2012.05.005_bib0055","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JCP.0b013e31820fcea3","article-title":"Metabolic effects of olanzapine in patients with newly diagnosed psychosis","volume":"31","author":"Fernandez-Egea","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.rpsm.2012.05.005_bib0060","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v62n0204","article-title":"Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia","volume":"62","author":"Kinon","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpsm.2012.05.005_bib0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.jcp.0000161501.65890.22","article-title":"Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders","volume":"25","author":"Kinon","year":"2005","journal-title":"J Clin Psychopharmacol"}],"container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989112001036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1888989112001036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:26:59Z","timestamp":1761823619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1888989112001036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1888989112001036"],"URL":"https:\/\/doi.org\/10.1016\/j.rpsm.2012.05.005","relation":{},"ISSN":["1888-9891"],"issn-type":[{"value":"1888-9891","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00bfDeber\u00eda considerarse la obesidad un factor limitante para el tratamiento con clozapina?","name":"articletitle","label":"Article Title"},{"value":"Revista de Psiquiatr\u00eda  y Salud Mental","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpsm.2012.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 SEP y SEPB. Published by Elsevier Espa\u00f1a, S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}